Skip to content

Repetitive Transcranial Magnetic Stimulation in Postpartum Depression

Repetitive Transcranial Magnetic Stimulation Effects on Clinical, Cognitive and Social Performance in Postpartum Depression

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01452321
Acronym
rTMSPPD
Enrollment
14
Registered
2011-10-14
Start date
2007-08-31
Completion date
2009-09-30
Last updated
2011-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Postpartum

Keywords

Transcranial Magnetic Stimulation;, Postpartum Depression;, Clinical Performance;, Cognitive Performance;, Social Performance

Brief summary

Several factors characterize repetitive transcranial magnetic stimulation (rTMS) as a strategic aid in the treatment of postpartum depression. However, up to current days there have been no studies evaluating the effects of rTMS on neurocognitive and social performance of women suffering from the disorder. The present study evaluates the impacts of rTMS in clinical, cognitive and social performance.

Detailed description

Transcranial magnetic stimulation is a noninvasive technique that can influence specific areas of the brain and has very few side effects. The treatment with transcranial magnetic stimulation requires attendance to hospital daily sessions for 4 consecutive weeks. Each session lasts up to 30 minutes. Side effects include scalp discomfort and mild headache. No anesthesia is required. Stimulation aims the dorsolateral prefrontal cortex, a region previously studied to treat depression symptoms with positive results. The present technique has never been employed in previous studies, but risks are insignificant.

Interventions

PROCEDURErepetitive transcranial magnetic stimulation (rTMS)

20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold. Site: Left Dorsolateral Prefrontal Cortex

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 36 Years
Healthy volunteers
No

Inclusion criteria

* major depression with a puerperal onset, according to the criteria of the DSM-IV-R (APA, 2000), as well as through a structured clinical interview (SCID-1/P v 2.0) * baseline score of at least 14 points on the Hamilton Depression rating Scale-17 items * baseline score of at least 13 points on the Edinburgh Postnatal Depression Scale. * range = 18-36 years * women who had given birth 1-6 months * any pharmacological treatment other than clonazepam (1 mg/day)

Exclusion criteria

* comprised ferromagnetic metallic implants * pacemakers * previous neurosurgery * history of seizures * major head trauma * alcoholism * drug addiction * any psychiatric or neurological disorder other than depression and anxiety * psychotic depression * suicidal propensities

Design outcomes

Primary

MeasureTime frameDescription
Hamilton Depression Rating Scale (HDRS)6 weeksReduction on the scores of HDRS (as on the scores of Edinburgh Pospartum Depression Scale and Hamilton Anxiety Scale; and improves the global clinical status in Clinical Global Impression, Global Assessment Scale and 36-item Short-form Health Survey - Quality of Life)

Secondary

MeasureTime frameDescription
Battery of Neuropsychological Tests and Social Adjustment Scale6 weeksPerformance of neuropsychological tests and social function - Trail Making Test, Wisconsin Card Sorting Test, Controlled Oral Word Association Test, Victoria Stroop Test, Rey Auditory Verbal Learning Test, WAIS-III (adapted for use in Brazil) subtests Similarities, Picture Completion, Digit Span, Digit-Symbol Coding and Social Adjustment Scale-Self Report (SAS-SR; adapted for use in Brazil)

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026